Labiotech.eu

gensight retinitis pigmentosa gene therapy

News and Trends 10 Jan 2018

French Biotech Starts Trials to Restore Sight in All Types of Retinitis Pigmentosa

GenSight will start a clinical trial in the UK testing a combination of gene therapy and a wearable device to restore sight in patients with retinitis pigmentosa. The UK Medicines and Healthcare Regulatory Agency (MHRA) has accepted GenSight’s application to run a first clinical trial in the UK testing a new type of therapy with the […]

January 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Jan 2018

These Dissolving Lenses Could Wash Away Glaucoma Patients’ Problems

Students at the Kaunas University of Technology, Lithuania, are developing dissolving contact lenses, which could help individuals suffering from glaucoma. A team of students from Kaunas University of Technology (KTU) won second place at the Silicon Valley Innovation Challenge in the Best Global Innovation category for their NanoLens technology. Their idea is to produce contact lenses that contain […]

January 10, 2018 - 3 minutesmins - By Alex Dale

Infographics 10 Jan 2018

Infographic: All You Need to Know About Checkpoint Inhibitors

Everything you need to know about what checkpoint inhibitors are and why they have caused a wave of hype for cancer immunotherapies. Since the approval of the first PD-1 checkpoint inhibitor, Keytruda, in 2014, there has been an explosion of the numbers of trials testing these drugs, both alone and in combination. The latest figure, […]

January 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Jan 2018

Biocartis and Amgen Shake Hands on Another Cancer Diagnostics Deal

Biocartis will use its expertise in molecular diagnostics to produce a companion diagnostic test for Amgen’s upcoming cancer drug. Biocartis has signed its second agreement with US pharma giant, Amgen, to develop a companion diagnostic to test the suitability of a drug for a specific patient. Both deals will make use of Biocartis’ Idylla platform, a fully automated […]

January 9, 2018 - 1 minutemin - By Alex Dale

News and Trends 9 Jan 2018

Scancell and BioNTech Will Combine Their Expertise to Fight Cancer

Scancell has brought in BioNTech to develop T-cell receptors against specific target proteins in cancer cells, opening the door to new cancer treatments that target them. Scancell works on immunotherapies for the treatment of cancer and it has announced that it will come together with Europe’s largest private biopharma, BioNTech, to develop T-cell receptor (TCR)-based therapies. […]

January 9, 2018 - 3 minutesmins - By Alex Dale

More News! 9 Jan 2018

Ablynx’ Stock Jumps by 60% After Rejecting Acquisition from Novo Nordisk

Ablynx has rejected a generous acquisition offer from Novo Nordisk. As a result, its stock has soared and is now worth more than what Novo offered in the first place. Early this morning, Novo Nordisk has made public an offer to acquire Ablynx, a Belgian biotech that has recently joined the European billion-euro biotech club. Novo […]

January 9, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Jan 2018

Adaptimmune Gets the Green Light for its New T-cell Cancer Therapy

Following successful pilot studies, Adaptimmune will increase the dose of its T-cell therapy 10-fold to see if it remains safe, while also assessing its cancer-fighting capacity. Adaptimmune is a leader in the development of T-cell therapies for the treatment of cancer. It has been testing another one of its SPEAR T-cells in two pilot studies to determine […]

January 9, 2018 - 3 minutesmins - By Alex Dale

News and Trends 8 Jan 2018

Bang and the Wart is Gone! Norwegian Peptide Destroys HPV-Infected Cells

Cytovation has raised over €3M to finish off pre-clinical testing of its treatment for warts, and to take it into the clinic. Norwegian biotech Cytovation is developing technology for the treatment of dermatological problems, including cutaneous warts caused by human papillomavirus. It lead candidate, CyPep-H1, uses a new mechanism of action to specifically target and destroy […]

January 8, 2018 - 3 minutesmins - By Alex Dale

News and Trends 8 Jan 2018

Galapagos Teams up with Dutch Biotech to Edit Fibrosis out of our RNA

Galapagos and ProQR will work together to target fibrosis using a technology to treat genetic diseases without permanent changes to the DNA. A new research collaboration between two biotech companies in Leiden, the Netherlands, will aim to discover a new class of drugs to treat fibrosis — a process of excessive scarring that leads to […]

January 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Jan 2018

And We’re Off! First Patient Dosed in this Spanish Biotech’s Rare Disease Trial

Minoryx Therapeutics has dosed the first patient in its Phase II/III trial for patients with adrenomyeloneuropathy, a condition that affects 1 in 17,000 newborns worldwide. Minoryx Therapeutics focuses on the development of new drugs for orphan diseases like adrenomyeloneuropathy. The first two patients in ADVANCE, a Phase II/III clinical trial of MIN-102, have started their treatment. The trial, […]

January 8, 2018 - 3 minutesmins - By Alex Dale

News and Trends 8 Jan 2018

Biotech in London Paves the Way for a New Therapy for Ulcerative Colitis

TopiVert has successfully completed a Phase I trial in ulcerative colitis with a new class of drug that could help reduce adverse side effects. The results of a Phase I trial run by London-based biotech TopiVert have shown potential for a new type of therapy for ulcerative colitis. The study revealed that the drug, called […]

January 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Jan 2018

This British Liquid Biopsy Could Save Us $5000 per Prostate Cancer Patient

ANGLE’s liquid biopsy technology measures the expression of an important prostate cancer biomarker, helping to identify the best treatment for different groups of patients. ANGLE is a world leader in the development of liquid biopsies – a technique for the early detection of cancer, which doesn’t require invasive tissue samples. The biotech published results in […]

January 8, 2018 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

French Biotech Starts Trials to Restore Sight in All Types of Retinitis Pigmentosa

These Dissolving Lenses Could Wash Away Glaucoma Patients’ Problems

Infographic: All You Need to Know About Checkpoint Inhibitors

Biocartis and Amgen Shake Hands on Another Cancer Diagnostics Deal

Scancell and BioNTech Will Combine Their Expertise to Fight Cancer

Ablynx’ Stock Jumps by 60% After Rejecting Acquisition from Novo Nordisk

Adaptimmune Gets the Green Light for its New T-cell Cancer Therapy

Bang and the Wart is Gone! Norwegian Peptide Destroys HPV-Infected Cells

Galapagos Teams up with Dutch Biotech to Edit Fibrosis out of our RNA

And We’re Off! First Patient Dosed in this Spanish Biotech’s Rare Disease Trial

Biotech in London Paves the Way for a New Therapy for Ulcerative Colitis

This British Liquid Biopsy Could Save Us $5000 per Prostate Cancer Patient

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!